Clinical Trials Browser

Phase 2 × Withdrawn × relatlimab × Clear all

NCT06400264 2024-05-06

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Phase 2 Withdrawn

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT03704077 2020-05-19

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Stomach Neoplasms